2026· The Innovation Medicine· Vol 4, pp. 100264· 0 citations· 99 references
TL;DR
The success of lung xenotransplantation will depend not on isolated technological breakthroughs but on the systematic integration of genetic engineering, immune modulation, and translational infrastructure, offering new hope to patients with end-stage lung disease.
Abstract
Lung transplantation remains the only curative treatment for end-stage lung diseases, yet a critical shortage of donor organs persists. Xenotransplantation using genetically modified pigs has emerged as a promising solution, with recent breakthroughs in cardiac and renal xenotransplantation demonstrating clinical feasibility. However, the unique anatomical and physiological characteristics of the lung pose distinct challenges that have delayed progress in pulmonary xenotransplantation. The first reported transplantation of a gene-edited pig lung into a brain-dead human recipient in 2025 represents a pivotal milestone, successfully preventing hyperacute rejection through triple-gene knockout combined with transgenic expression of human complement regulatory proteins and thrombomodulin. Yet the nine-day observation window revealed persistent challenges, including severe primary graft dysfunction and active antibody-mediated injury, highlighting that current genetic modifications remain inadequate for achieving long-term graft survival. This review systematically analyzes the layered immunological and physiological barriers to lung xenotransplantation and evaluates evolving intervention strategies that reflect a paradigm shift from passive molecular camouflage toward active immunological remodeling. Looking beyond biological barriers, successful clinical translation requires integrated solutions spanning scalable donor production systems, surgical adaptation, rigorous biosafety frameworks, ex vivo perfusion platforms, and non-invasive monitoring technologies. Ultimately, the success of lung xenotransplantation will depend not on isolated technological breakthroughs but on the systematic integration of genetic engineering, immune modulation, and translational infrastructure, offering new hope to patients with end-stage lung disease.
Advanced heart failure affects over 6 million adults in the United States alone. Orthotopic heart transplantation remains the definitive treatment, with over 90% one-year survival and meaningful gains in functional status and quality of life. The therapy is, however, constrained by an intractable supply problem. For de...
A. Abdelrehim, D. Hurst, W. H. Gray et al.· Frontiers in Transplantation· 0 citations
The use of multiomics as a hypothesis-generating tool to guide next-generation donor-pig design and adjust immunosuppression is summarized, while exploring its contribution to the diagnosis of xenograft rejection.
J. Ladowski, A. Sannier, A. Loupy et al.· American Journal of Transpla...· 0 citations
Solid organ xenotransplantation is moving into early clinical use, whereas living xenogeneic cells and tissues are being developed for distinct therapeutic tasks. Product-based discussions can obscure differences in required functional duration, immune exposure, consequences of product loss, and acceptable treatment bu...
H. Hara· Clinical transplantation and...· 0 citations
Lung transplantation (LTx) remains the only definitive therapy for selected patients with end-stage lung disease, yet outcomes are limited by early ischemia-reperfusion injury (IRI) and primary graft dysfunction (PGD), and by chronic lung allograft dysfunction (CLAD) as the leading cause of late graft failure. These en...
F. Olm, P. Kortleven, M. Mittendorfer et al.· The Journal of Heart and Lun...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.